Targeted therapies for rare lung diseases


Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis.


Avalyn is developing inhaled formulations of approved medications to treat rare respiratory diseases. Our initial focus is on the treatment of Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis, and rare diseases that have dramatic impacts on patient quality of life.


March 6, 2024

Avalyn to Participate in Leerink Partners Global Biopharma Conference
Read more »

February 6, 2024

Avalyn to Participate in Multiple Upcoming Investor Conferences
Read more »

December 6, 2023

Avalyn to Participate in the 2023 RBC Capital Markets Healthcare Private Company Conference
Read more »

November 9, 2023

Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis
Read more »